All News
TNR - Steroids and PMR
In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.
Read Article53.2 Million with Diagnosed Arthritis (USA: 2019–2021)
This week the CDC's MMWR reports that during 2019–2021, 21.2% of U.S. adults (53.2 million) reported "diagnosed arthritis".
Read ArticleFDA Approves IV Secukinumab
On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
Read Article
Felson reports a novel model to study knee OA. 2,340 Adults from the MOON study undergoing post-traumatic ACL reconstructions (ACLR), 16-26% identified w/ continued w/ knee pain & at risk for accelerated #OA -->study of interventions https://t.co/rDaNmeCGXM https://t.co/tm0kZ2ax78
Dr. John Cush RheumNow ( View Tweet)

In 2024, the new Samsung Galaxy watch will be able to detect sleep apnea using the Samsung Health Monitor app that monitors BP, ECG, irregular heart rhythm, and blood O2 levels. Approved by Korea’s Ministry of Food and Drug Safety for use in Korea. https://t.co/ijWNzYWiF5 https://t.co/2nRkgzuYfI
Dr. John Cush RheumNow ( View Tweet)

It's so important to diagnose psoriatic arthritis early. If you have psoriasis please join the HPOS study at https://t.co/xBBFj4npgo https://t.co/qBxDzr2IZZ
LauraCoates ( View Tweet)

Electronic survey of US rheumatology fellows assessed burnout in Fellows using Maslach Burnout Inventory. Only 18% (105/582) of ped & adult fellows responded; 38% PGY4s & 17% PGY5/6 had 1+ burnout Sxs. 13% PGY4 fellows met criteria for depression https://t.co/6Bhrpl1LCW https://t.co/99snXAUFa4
Dr. John Cush RheumNow ( View Tweet)

Long-term Safety of a JAKi in Patients with RA With up to 6.5 Years of Exposure
View this poster on the long-term integrated safety data with a JAKi in patients with RA from 6 clinical studies. Sponsored by AbbVie US Medical Affairs https://t.co/q6Mlr78XFG. https://t.co/neMnFDSRze
Dr. John Cush RheumNow ( View Tweet)

Full Read review of #PMR in Lancet:
- Start @ 12·5–25mg prednisone qd
- Remission in most but, relapses in 40–60%
- Onset sudden; AM stiffness predominates; Shoulders>Pelvic
~50% have distal MSK Sxs
- US: look for B/L sub-acromial/deltoid bursitis https://t.co/GJDGjOD7oX https://t.co/nWMW3HB0YK
Links:
Dr. John Cush RheumNow ( View Tweet)

#PMR Mimics: PMR vs RA?
Dr. Robert Spiera (New York) discusses mimics of polymyalgia rheumatica. This is part of a video series produced by RheumNow for its October 2023 campaign, Make Rheum for PMR.
https://t.co/MI06ERq1qI https://t.co/UBhha3DjNa
Links:
Dr. John Cush RheumNow ( View Tweet)

#PMR: glad or bad tidings?
Please don’t tell your patient that PMR “typically” lasts two years. Because it probably won’t last exactly two years, and then they’ll be less inclined to believe other things you say.
Read more...
https://t.co/ET9OPa7yjq
@sarah_L_mackie https://t.co/0axS6AVQV3
Dr. John Cush RheumNow ( View Tweet)

Shoulder Arthralgias
Featuring Dr. David Liew (Melbourne, Australia) ( @drdavidliew )
Cancer, checkpoint inhibitors and arthralgias. #PMR
https://t.co/FRpIzfnW76 https://t.co/2S3PP1WA3O
Dr. John Cush RheumNow ( View Tweet)

342 systemic sclerosis pts, ~32% report reproductive probs:
-early menopause onset (45 vs 48y)
-menopause effected by SSc onset & digital ulcers
-More spont Abs(12 vs 4%), premies (22 vs 6%), low birth Wt (27 vs 5%), C-section (49 vs 19%); NOT Infertility https://t.co/Tjjl9sxtja https://t.co/LKzyGR0mlE
Dr. John Cush RheumNow ( View Tweet)


Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/P4Vv2L3u24 https://t.co/ZYBPcgXNi8
Dr. John Cush RheumNow ( View Tweet)

JAKi Safety and Efficacy in bDMARD-IR Patients with RA
View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.https://t.co/Qr3KJXZJOe https://t.co/Ri1eS0q9Rb
Dr. John Cush RheumNow ( View Tweet)

Difficult #PMR Management
Featuring Dr. Sebastian Sattui (Pittsburgh, PA) PMR with Difficulty Weaning plus Synovitis. QD Clinics are video vignettes with lessons from the clinic.
https://t.co/dLYxwrmbJg
@sattuiSEMD https://t.co/FDuHWJT7Ra
Dr. John Cush RheumNow ( View Tweet)

PMR & Popeye's Spinach
Dr. Jack Cush reviews the big #PMR reports from this week along with other journal reports from RheumNow.
https://t.co/7oCQmuSATE https://t.co/5qWfZZzNBn
Dr. John Cush RheumNow ( View Tweet)

Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis #RA
https://t.co/BhAKRXuzMY https://t.co/MqVHMieqiz https://t.co/zCvO2FbrZA
Dr. John Cush RheumNow ( View Tweet)

FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9
Dr. John Cush RheumNow ( View Tweet)